Renal complications of high-dose chemotherapy and peripheral blood stem cell transplantation

Nephron

Volumn 84, Issue 2, 2000, Pages 136-141

  Herget Rosenthal, Stefan ^a   Uppenkamp, Michael ^b   Beelen, Dietrich ^b   Kohl, Detlev ^b   Kribben, Andreas ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b NONE

Author keywords

Acute renal failure; Nephrotoxicity; Peripheral blood stem cell transplantation; Proteinuria; Sepsis

Indexed keywords

AMINOGLYCOSIDE; CARBOPLATIN; CARMUSTINE; CEPHALOSPORIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; MELPHALAN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER; CHEMOTHERAPY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG MEGADOSE; FEMALE; GRAFT REJECTION; HEMATOLOGIC DISEASE; HEMODIALYSIS; HUMAN; INCIDENCE; KIDNEY PERFUSION; KIDNEY TUBULE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROTOXICITY; OUTCOMES RESEARCH; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; SEPSIS; SEPTIC SHOCK; STEM CELL TRANSPLANTATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0033973966     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000045561     Document Type: Article

References (42)

1. Smith DM, Weisenburgr DD, Bierman P, Kessinger A, Vaughan WP, Armitage JO: Acute renal failure associated with autologous bone marrow transplantation. Bone Marrow Transplant 1987;2:195-201.
2. Zager RA, O'Quigley J, Zager BK, Alpers CE, Shulman HM, Gamelin LM, Steward P, Thomas ED: Acute renal failure following bone marrow transplantation: A retrospetive study of 272 patients. Am J Kidney Dis 1989;13: 210-216.
3. Kone BC, Whelton A, Santos G, Saral R, Watson AJ: Hypertension and renal dysfunction in bone marrow transplant recipients. Q J Med 1988;69:985-995.
4. To LB, Haylock DN, Simmons PJ, Juttner CA: The biology and clinical uses of blood stem cells. Blood 1997;89:2233-2258.
5. Van Warmerdam LJC, Rodenhuis S, Van der Wall E, Maes RAA, Beijnen JH: Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. Br J Cancer 1996; 76:979-984.
6. Bokemeyer C, Franzke A, Hartmann JT, Schoeber C, Arseniev L, Metzner B, Link H, Kanz L, Schmoll HJ: A phase I/II study of sequential, dose-escalated, high-dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997;80: 1221-1227.
7. Goss G, Szer J, Basser R, Fox R, Grigg A: Multiple cycles of aggressive chemotherapy prior to autologous peripheral stem cell transplantation for lymphoma. Aust NZ J Med 1997;27:323-329.
8. Huober J, Schneeweiss A, Hohaus S, Wittmann G. Meyer A, Martin S, Goldschmidt H, Bastert G, Haas R, Wallwiener D: Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer. J Cancer Res Clin Oncol 1998;124:690-694.
9. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Bruckner CD: Bone marrow transplantation. N Engl J Med 1975;292:895-902.
10. Reece DE, Connors JM, Spinelli JJ, Barnett MJ, Fairey RN, Klingemann HG, Nantel SH, O'Reilly S, Shepherd JD, Sutherland HJ, Voss N, Chan K, Phillips GL: Intensive therapy with cyclophosphamide, carmustine, etoposide + cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83:1193-1199.
11. Gribben JG, Linch DC, Singer CRJ, McMillan AK, Jarrett M, Goldstone AH: Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989;73:340-344.
12. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RMH, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-1655.
13. Shulman HM, Hinterberger W: Hepatic venoocclusive disease - liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992;10:197-214.
14. Nichols CR, Tricot G, Williams SD, Van Besien K, Loehrer PJ, Roth BJ, Akard L, Hoffman R, Goulet R, Wolff SN, Giannone L, Greer J, Einhorn LH, Jansen J: Dose-intensive chemotherapy in refractory germ cell cancer - a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989;7:932-939.
15. Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, Schnipper L, Frei E, Henner WD: A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 1989;7:651-661.
16. Cooper BW, Creger RJ, Soegiarso W, Mackay WL, Lazarus HM: Renal dysfunction during high-dose cisplatin therapy and autologous hematopoietic stem cell transplantation: Effect of aminoglycoside therapy. Am J Med 1993;94: 497-504.
17. Starko R, Karim M, Shepherd J: Acute renal failure following bone marrow transplantation: Incidence, outcome and risk (abstract). J Am Soc Nephrol 1993;4:325.
18. Lane PH, Mauer SM, Blazar BR, Ramsay NKC, Kashtan CE: Outcome of dialysis for acute renal failure in pediatric bone marrow transplant patients. Bone Marrow Transplant 1994;13:613-617.
19. Fields KK, Elfenbein GJ, Lazarus HM, Cooper BW, Perkins JB, Creger RJ, Ballester OF, Hiemenz JH, Janssen WE, Zorsky PE: Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: Toxicity profile. J Clin Oncol 1995;13:323-332.
20. Gruss E, Bernis C, Tomas JF, Garcia-Canton C, Motellon JL, Paraiso V, Traver JA, Fernandez-Ranada RM: Acute renal failure in patients following bone marow transplantation: Prevalence, risk factors and outcome. Am J Nephrol 1995;15:473-479.
21. Jacobs AA, Stevens DA, Brier ME: Predictive variables for acute renal failure and mortality in bone marrow transplantation (abstract). J Am Soc Nephrol 1995;5:395.
22. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonncveld P, Gisselbrecht C, Cahn JY, Harousseau JL, Coiffier B, Biron P, Mandelli F, Chauvin F: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545.
23. Merouani A, Shpall EJ, Jones RB, Archer PG, Schrier RW: Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. Kidney Int 1996;50:1026-1031.
24. Ter Wee PM, Mahesh S, Aufenacker THJ, Huijgens PC, Gans ROB: Autologous bone marrow/stem cell transplantation: Risk for development of renal failure (abstract). J Am Soc Nephrol 1996;7:1378.
25. Agaliotis DP, Ballester OF, Mattox T, Hiemenz JW, Fields KK, Zorsky PE, Goldstein SC, Perkins JB, Rosen RM, Elfenbein GJ: Nephrotoxicity of high-dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem cell transplantation. Am J Med Sci 1997;314:292-298.
26. Anderson RJ, Linas SL, Berns AS, Henrich WL, Miller TR, Gabow PA, Schrier RW: Nonoliguric acute renal failure. N Engl J Med 1977; 296:1134-1138.
27. Solomon R, Werner C, Mann D, D'Elia J, Silva P: Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331: 1416-1420.
28. Better OS, Stein JH: Early management of shock and prophylaxis of acute renal failure in traumatic rhabdomyolysis. N Engl J Med 1990; 322:825-829.
29. Van der Lelie H, Baars JW, Rodenhuis S, Van Dijk MA, De Glas-Vos CW, Thomas BLM, Van Oers RHJ, Von dem Boorne AEG: Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support. Cancer 1995;76:2338-2342.
30. Nademanee A, O'Donnell MR, Snyder DS, Schmidt GM, Parker PM, Stien SA, Smith EP, Molina A, Stepan DE, Somlo G, Margolin KA, Sniecinski I, Dagis AC, Niland J, Pezner R, Forman SJ: High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease. Blood 1995;85:1381-1390.
31. Watanabe K, Iwaki H, Satoh M, Ikeda T, Ichimiya S, Suzuki N, Kudoh T, Oda T, Matsuura A, Mori M, Kikuchi K: Veno-occlusive disease of the liver following bone marrow transplantation: A clinical-pathological study of autopsy cases. Artif Organs 1996;20:1145-1150.
32. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA: Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993;118:255-267.
33. Fink JC, Cooper MA, Burkhart KM, McDonald GB, Zager ZA: Marked enzymuria after bone marrow transplantation: A correlate of veno-occlusive disease-induced 'hepatorenal syndrome'. J Am Soc Nephrol 1995;6:1655-1660.
34. Grigg A, Szer J, Skov K, Barnett M: Multiorgan dysfunction associated with high-dose carboplatin therapy prior to autologous transplantation. Bone Marrow Transplant 1994;17:67-74.
35. Goetz MB, Sayers J: Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993;32:325-334.
36. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH: Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990;25:679-687.
37. Churchill DN, Seely J: Nephrotoxicity associated with combined gentamicin-amphotericin B therapy. Nephron 1977;19:176-181.
38. Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, Gonin R, McCauley M, Mazanet R, Schnipper L, Frei E, Antman KH: Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant 1995; 15:373-379.
39. Zager RA: Gentamicin nephrotoxicity in the setting of acute renal hypoperfusion. Am J Physiol 1988;254:F574-F581.
40. Zager RA, Prior RB: Gentamicin and gram-negative bacteremia. J Clin Invest 1986;78: 196-204.
41. Menashe PI, Ross SA, Gottlieb JE: Acquired renal insufficiency in critically ill patients. Crit Care Med 1988;16:1106-1109.
42. Rasmussen HH, Ibels LS: Acute renal failure: Multivariate analysis of causes and risk factors. Am J Med 1982;73:211-218.